InnoServ taps new chief executive
Independent service organization InnoServ Technologies of Corona,CA, has named Michael Puls as president and CEO. Puls fills aleadership role formerly held by Alan Margulis, who left the companyin March (SCAN 3/29/95). Puls moves to InnoServ from Senmed
Independent service organization InnoServ Technologies of Corona,CA, has named Michael Puls as president and CEO. Puls fills aleadership role formerly held by Alan Margulis, who left the companyin March (SCAN 3/29/95). Puls moves to InnoServ from Senmed MedicalVentures, which specializes in medical venture capital financing.
InnoServ reported second-quarter financial results (end-October)earlier this month. Revenues were $11.9 million with net incomeof $185,000, compared to sales of $13.4 million and a net lossof $528,000 in the same period last year.
For the first six months of the year, InnoServ posted revenuesof $23.9 million with net income of $71,000, compared to revenuesof $22.1 million and a net loss of $1.1 million in the same periodin 1994. InnoServ also announced that it had received a five-year$5.5 million contract for biomedical and clinical lab repair servicesat Children's Hospital in Columbus, OH.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
